The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system.
Biogen Idec today announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the company’s...
Biogen Idec has submitted a new injectable multiple sclerosis drug to the Food and Drug...
Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.
Biogen Idec has completed its purchase of Elan Corporation’s interest in TYSABRI ® (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013.
Biogen Idec today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,399,514, which offers additional protection for TECFIDERA™ (dimethyl fumarate), the company’s oral therapeutic candidate for the treatment of multiple sclerosis (MS). The patent, which will expire in 2028, covers the dosing regimen of daily administration of 480 mg of TECFIDERA.
Biogen Idec announced today that the company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia BMarch 4, 2013 7:50 am | News | Comments
Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline.
The Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
Biogen Idec Inc. has announced full year and fourth quarter 2012 results.
Biogen Idec said a potential multiple sclerosis treatment designed to last longer between injections fared well in late-stage research, and the drug developer plans to submit it to U.S. and European regulators for possible approval this year.
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MSJanuary 17, 2013 3:25 am | News | Comments
Biogen Idec and Elan Corporation have submitted applications to the FDA and European Medicines Agency (EMA) requesting updates to the TYSABRI ® (natalizumab) labels.
WESTON, Mass. (AP) — Biogen Idec is halting the development of an experimental treatment for Lou Gehrig's disease after a late-stage study.
Biogen Idec announced today that it has created a new research consortium in collaboration with several leading academic research centers that will leverage a range of scientific techniques and disciplines to identify new approaches to treating amyotrophic lateral sclerosis (ALS).
Biogen Idec and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both companies’ Research Triangle Park (RTP)-based facilities.
Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs to Treat Neurological DisordersDecember 11, 2012 3:21 am | News | Comments
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.
Biogen Idec has dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus
Shares of Biogen Idec Inc. continued to slump Friday after the company said the Food and Drug Administration has delayed a decision on its multiple sclerosis pill BG-12.
WASHINGTON (AP) — Biogen Idec has received U.S. approval for an easier-to-use injection device for its multiple sclerosis drug Avonex.
Samsung Biologics and Biogen Idec announced today that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December.
Biogen Idec and Stromedix, Inc. today announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc., a privately held biotechnology company focused on innovative therapies for fibrosis and organ failure.
Biogen Idec Inc., a global biotechnology company contentrating on the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular AtrophyJanuary 4, 2012 3:39 am | News | Comments
Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis’ antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy (SMA).
Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.
Biogen Idec today announced the company will acquire 100% of Dompe shares in its joint ventures in both Italy and Switzerland. This integration is part of Biogen Idec's and Dompe Group's broader strategy to focus on each company's respective core business.
Biogen Idec Inc. and Abbott Laboratories said Tuesday that multiple sclerosis drug candidate daclizumab worked better than a placebo at preventing a relapse of symptoms during a mid-stage clinical trial.